Showing 31 - 40 of 82,022
Persistent link: https://www.econbiz.de/10013290794
This report updates the 2006 analysis in line with the present requirements of BIS.Techniques used in patent landscaping have also evolved since the first report so the analysis in this project is specifically based around the country of residence of patent applicants.This gives a better...
Persistent link: https://www.econbiz.de/10013291034
This paper models how the evolving field of pharmacogenomics (PG), which is the science of using genomic markers to predict drug response, may impact drug development times, attrition rates, costs, and the future returns to research and development (R&D). While there still remains an abundance...
Persistent link: https://www.econbiz.de/10012466796
Biologics accounted for roughly $145 billion in spending in 2018 (IQVIA, 2019). They are also the fastest growing segment of the pharmaceutical industry. The Biological Price Competition and Innovation Act (BPCIA) of 2010 created an abbreviated pathway for biosimilar products to promote price...
Persistent link: https://www.econbiz.de/10012496071
Persistent link: https://www.econbiz.de/10012005044
Persistent link: https://www.econbiz.de/10012020065
Persistent link: https://www.econbiz.de/10011881393
Persistent link: https://www.econbiz.de/10011932611
Persistent link: https://www.econbiz.de/10011785403
Pharmacogenomics, or the application of genetic testing to guide drug selection and/or dosing, is often cited as integral to the vision of how precision medicine can be integrated into routine clinical practice. Yet despite a growing base of scientific discovery on genetic variation that...
Persistent link: https://www.econbiz.de/10012453580